Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

October 30, 2026

To whom it may concern:

(Change in Disclosure Information) Notice of Change in the Date of Execution of the Share Transfer Concerning the Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation (Making It a Wholly Owned Subsidiary)

Towa Pharmaceutical Co., Ltd. (hereinafter, the "Company") announces that, regarding the acquisition of shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation to make it a wholly owned subsidiary and the transfer of manufacturing and marketing approvals, which were approved by the Board of Directors of the Company on July 3, 2026, it has decided to change the date of execution of the share transfer from Tanabe Pharma Corporation as described below.

For details on this matter, see "Notice of Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation (Making It a Wholly Owned Subsidiary) and Transfer of Manufacturing and Marketing Approvals," dated July 3, 2026.

1. Details of the change

Item	Before change	After change
Date of execution of share transfer	End of November 2026 (planned)	End of December 2026 (planned)

2. Reason for the change

In order to ensure a smooth business integration following the share acquisition, both companies have been carefully reviewing the transition process and have agreed to change the date of execution of the share transfer to the end of December in order to secure sufficient preparation time.

3. Future outlook

The impact of this change in the date of execution of share transfer on the Company's consolidated financial forecasts for the fiscal year ending March 2027 is minor. Negative goodwill is expected to be recognized from the share acquisition. We will promptly announce the goodwill amount and the impact on the Company's consolidated financial forecasts for the fiscal year ending March 2027 as soon as the details are finalized.

End of Notice